Jesduvroq

Increased risk for thrombotic vascular events (may be fatal), including myocardial infarction (MI), stroke, venous thromboembolism, vascular access thrombosis; evaluate if occurs. History of MI, cerebrovascular event, or acute coronary syndrome within 3mos prior to initiation; not recommended. Preexisting history of heart failure increases risk for hospitalization. Monitor BP periodically. History of GI erosions, peptic ulcer disease, concomitant medications that increase risk of GI erosion, tobacco smokers, use of alcohol. Active malignancies: not recommended. Correct and exclude other causes of anemia (eg, vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding) prior to initiation. Evaluate iron levels prior to and during treatment; give supplemental iron when serum ferritin <100mcg/mL or serum transferrin saturation <20%. Assess ALT, AST, ALP, total bilirubin prior to initiation; repeat tests if signs of liver disease develop. Monitor Hgb every 2 weeks for the first month, then every 4 weeks thereafter, following therapy initiation and after each dose adjustment. Moderate hepatic impairment: reduce initial dose. Severe hepatic impairment: not recommended. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).